Zanzalintinib is under clinical development by Exelixis and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase I drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Zanzalintinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zanzalintinib (XL-092) is under development for the treatment of solid tumors such as metastatic renal cell carcinoma, metastatic urothelial carcinoma including the renal pelvis, ureter, urinary bladder, or urethra, metastatic castration resistant prostate cancer, metastatic hepatocellular carcinoma, papillary renal cell carcinoma, recurrent head and neck cancer squamous cell carcinoma, oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, and laryngeal cancer and hormone receptor-positive breast cancer. The drug candidate is administered through oral route. It acts by targeting protein tyrosine kinases which constitutes of MET, VEGFR, AXL and MER.
It was under development for the treatment of non-small cell lung cancer.
Exelixis is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company’s marketed products include, Cometriq (cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). The company’s pipeline product candidates include XL092 for the treatment of advanced solid malignancies and XL888, an ATP-competitive inhibitor of HSP90, and others. The company has collaborative partnerships with biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in Alameda, California, the US.
For a complete picture of Zanzalintinib’s drug-specific PTSR and LoA scores, buy the report here.